Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is an American biotechnology enterprise developing immune-sequencing diagnostics for disease detection. The company structures its operational focus across two primary areas: Minimal Residual Disease (MRD) testing and Immune Medicine discovery. Its core commercial product is clonoSEQ, an FDA-cleared diagnostic for tracking residual disease in blood cancers, alongside immuno-sequencing research tools. Primary revenue is derived from clinical diagnostic testing fees alongside biopharmaceutical research collaboration and licensing payments. Adaptive Biotechnologies holds a leading market position in adaptive immune system decoding and clinical MRD testing. The company is headquartered in Seattle, Washington, and its shares trade on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Adaptive Biotechnologies.
- Legal name
- Adaptive Biotechnologies Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
- Exposure themes
- Genomics & Profiling, Immune Repertoire Profiling, Precision Medicine & Genomics
Funds holding Adaptive Biotechnologies
- BNP Health Care Innovators — BNP Paribas · 1.27 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.89 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.43 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.29 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.28 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.06 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)